secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001104659-23-073326
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccitech reports positive final Phase 1b/2 HBV002 data; two patients achieve non-detectable HBsAg
--------------------------------------------------------------------------------

- Two of five patients with baseline HBsAg <100 IU/mL in Group 3 developed non-detectable HBsAg, sustained eight months after last dose.
- Group 3 mean HBsAg reduction 0.76 log10 at 2 months (p<0.001) and 0.98 log10 at 8 months (p<0.001).
- VTP-300 monotherapy in Group 2 showed 0.7-1.4 log10 declines in three participants; robust T cell response correlated with HBsAg decline.
- Phase 2b trial HBV003 >40% enrolled (48/120); interim data expected Q4 2023.
- Phase 2a trial with Arbutus (VTP-300 after AB-729) in 40 patients; interim data expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923073326/0001104659-23-073326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923073326/tm2319306d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-073326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer